Clinical response to sodium glucose co-transporter 2 inhibitor ipragliflozin in a patient with metastatic renal cell carcinoma.
diabetes mellitus
renal cell carcinoma
sodium glucose transporter 2 inhibitor
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
08
04
2019
accepted:
01
06
2019
entrez:
4
8
2020
pubmed:
26
6
2019
medline:
26
6
2019
Statut:
epublish
Résumé
Sodium glucose co-transporter 2 inhibitors constitute a new class of antidiabetic medication. Sodium glucose co-transporter 2 inhibitors have been shown to exert anticancer effects. However, the clinical value of these drugs as anticancer agents is yet to be evaluated. A 72-year-old man presented to our hospital with frequent cough and dyspnea. Contrast-enhanced computed tomography revealed renal cell carcinoma cT3bN0M1. Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, treatment was initiated to control blood glucose levels. Two years after diagnosis, computed tomography revealed remarkable tumor regression without any systemic therapy other than ipragliflozin. Sodium glucose co-transporter 2 inhibitors are potentially applicable as anticancer agents among patients with metastatic renal cell carcinoma.
Identifiants
pubmed: 32743434
doi: 10.1002/iju5.12099
pii: IJU512099
pmc: PMC7292183
doi:
Types de publication
Case Reports
Langues
eng
Pagination
269-271Informations de copyright
© 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Am J Physiol Renal Physiol. 2001 Jan;280(1):F10-8
pubmed: 11133510
Med Sci Monit. 2017 Aug 01;23:3737-3745
pubmed: 28763435
Pharmacol Ther. 2017 Feb;170:148-165
pubmed: 27773781
World J Urol. 2010 Jun;28(3):295-301
pubmed: 20364382
Int J Cancer. 2018 Apr 15;142(8):1712-1722
pubmed: 29205334